The key takeaway from the researcher's for me in A
Post# of 72440
is the TP53 findings.
An absolute huge unmet need in Relapse/Refractory AML
and late stage MDS in older patients.It has been widely speculated from numerous other trial data that regulation of the P53 gene is the
key to this subset.
Cheers'